INTRODUCTION
============

The cytochrome P450 (CYP) enzyme CYP2B6 is one of about a dozen human CYPs that are primarily involved in the biotransformation of drugs and other xenobiotics. The *CYP2B6* gene and its closely related pseudogene, *CYP2B7*, are located in a tandem head-to-tail arrangement within a large *CYP2* gene cluster on the long arm of chromosome 19 ([@B50]; **Figure [1](#F1){ref-type="fig"}**). The orthologous genes in dog, mouse, and rat are termed *CYP2B11*, *Cyp2b10*, and *CYP2B1*, respectively, but in contrast to other mammalian species, CYP2B6 is the only functional isozyme of its subfamily in humans ([@B92]). Owing to the existence of extensive genetic polymorphism as well as strong inhibitors and inducers, its activity is highly variable in the population. For some clinically used drugs including the antiretroviral agents efavirenz and nevirapine, *CYP2B6*single nucleotide polymorphisms have been shown to be useful predictors of pharmacokinetics and drug response (reviewed in [@B154]; [@B128]; [@B106]). However, recent data indicate that pharmacogenetic mechanisms are complex, appear on several levels of gene expression from the initial mRNA transcript to splice variants (pre-mRNA splicing and mRNA expression) to altered proteins, and affect function in various ways including substrate-dependent and substrate-independent effects. Several previous reviews are available that cover the biochemical pharmacology, molecular genetics, and pharmacogenetics of this enzyme at various degrees of detail ([@B26]; [@B132]; [@B49]; [@B154]; [@B139]; [@B89]; [@B135]). The purpose of this review is to summarize recent advances in areas that have an impact on variable expression of CYP2B6 and the mechanisms and impact of *CYP2B6*polymorphism, as observed by various *in vitro*approaches as well as in *in vivo*studies, and to discuss their functional and clinical implications.

![**Structure of genomic regions on chromosome 19**. Schematic representation of the *CYP2ABFGST-*cluster on chromosome 19 **(A)** and of the *CYP2B6* gene **(B)**. Boxes in the **(A)** represent genes, with direction of transcription indicated by arrows. The **(B)** represents CYP2B6 exons and introns and shows the most important SNPs as triangles.](fgene-04-00024-g001){#F1}

VARIABILITY OF EXPRESSION AND TRANSCRIPTIONAL REGULATION
========================================================

Cytochrome P450 2B6 is primarily expressed in the liver where its contribution to the total microsomal P450 pool has been estimated to be within a range of about 1--10%, with a large inter-individual variability at protein level of roughly 100-fold (see [@B154] for review and references therein). Although some earlier studies reported expression in only a fraction of human livers, newer studies with better antibodies found CYP2B6 to be present in all investigated human adult liver samples ([@B51]) while up to one-third of pediatric samples contained no detectable protein ([@B18]). In the latter study, ontogenic differences were studied in liver microsomes from 217 pediatric liver donors. Hepatic median CYP2B6 protein levels were about twofold higher in the period between birth and 30 days postnatal compared to fetal samples, and protein levels varied already over 25-fold in both of these age groups ([@B18]). Maturation effects may further depend on genotype, as suggested in a study on HIV-infected children treated with efavirenz ([@B124]; [@B137]; [@B31], [@B32]).

One of the most important factors contributing to intra- as well as inter-individual variability is enzyme induction, i.e., *de novo* protein synthesis following exposure to certain chemicals. Regulation of *CYP2B*gene expression represents the archetypal example of enzyme induction ([@B108]). Human CYP2B6 is strongly inducible by several drugs including "classical" inducers such as rifampicin, phenytoin, and phenobarbital involving a so-called phenobarbital-responsive enhancer module (PBREM) at -1.7 kb of the *CYP2B6*gene promoter, and a distal xenobiotics-responsive enhancer module (XREM, -8.5 kb), to which pregnane X receptor (PXR, *NR1I2*) and/or constitutive androstane receptor (CAR, *NR1I3*) bind to mediate increased transcription ([@B124]; [@B137]; [@B31], [@B32]). Since other CYPs are regulated by overlapping sets of nuclear receptors, CYP2B6 is often co-induced with CYP2C enzymes and CYP3A4. CYP2B6 inducers identified to date include cyclophosphamide ([@B39]), hyperforin ([@B41]), artemisinin antimalarials ([@B119]; [@B11]), carbamazepine ([@B98]; [@B21]), metamizole ([@B117]; [@B102]), ritonavir ([@B62]), the insect repellent *N*,*N*-diethyl-*m*-toluamide (DEET; [@B19]), statins ([@B33]), efavirenz ([@B93]; [@B43]). Interestingly, in the latter study, gender influenced the inducibility of efavirenz 8-hydroxylation, which was higher in women than in the men ([@B93]). In addition to therapeutic drugs, pesticides were found to be powerful inducers of CYP2B6 and other CYPs through interaction with both PXR and CAR ([@B19]). Induction of CYP2B6 and other cytochromes P450 and its clinical consequences has been reviewed by others ([@B99]; [@B89]).

Sex differences in liver expression have been observed in a number of studies. Females liver donors had higher amounts of CYP2B6 mRNA (3.9-fold), protein (1.7-fold), and enzyme activity (1.6-fold) compared to male subjects in a study of 80 ethnically mixed samples ([@B68]). In a study with 235 Caucasian liver donors, female samples had 1.6-fold higher expression level of CYP2B6 mRNA, however, this difference did not translate into higher protein and activity levels and no sex difference was found when only liver donors without presurgical drug exposure were considered ([@B51]). Discrepant effects of sex on pharmacokinetics of CYP2B6 substrates, which may be due to other confounders such as age or smoking status, were also found *in vivo*. Higher bupropion hydroxylation rates were found in adolescent females compared to males ([@B123]) but not in adults ([@B54]). For efavirenz, several studies reported elevated plasma concentrations in female compared to male patients, which is in contrast to the above-mentioned *in vitro* findings and may be explained by other factors such as differences in body fat content and distribution ([@B10]; [@B96]; [@B90]). The influence of age on CYP2B6 expression may also depend on sex, as only males showed a significant increase of liver CYP2B6 at higher age ([@B149]).

Besides liver, CYP2B6 is also consistently expressed in different parts of respiratory and gastrointestinal tracts, including lung and nasal mucosa, and also in skin and the kidneys ([@B13]; [@B22]; [@B129]; [@B71]). The significance of CYP2B6 in these extrahepatic tissues is currently unknown, but it should be remembered that the enzyme is probably the most important one for many environmental toxins such as pesticides, and its presence in tissues with barrier function may thus contribute substantially to protection against these chemicals. In addition, the presence of CYP2B6 in brain has been demonstrated in human and primate brain tissue samples and smoking, alcohol consumption, and genetic polymorphism have been suggested to contribute to its variability in this organ ([@B88]). In general, CYP levels in extrahepatic tissues are far below those of liver, but the localization to specific regions in the brain may contribute to the activation or inactivation of centrally acting drugs and to neurological side effects of certain medications or abused drugs, e.g., "ecstasy" \[1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), see below\]. This may also explain why efficacy for some centrally acting drugs is not well correlated to their plasma levels. The potential role of brain-expressed CYPs including CYP2B6 in the biotransformation of centrally acting drugs has been reviewed by others ([@B87]; [@B34]).

THE CHEMICAL INTERACTION PROFILE OF CYP2B6
==========================================

Recent studies have revealed crystal structures of the CYP2B6 wild-type and K262R variant in complex with various inhibitors at providing first views into its active site and its plasticity to adopt different conformations when binding different ligands ([@B38]; [@B118]; [@B142]). Substrates of CYP2B6 are usually fairly lipophilic, neutral or weakly basic non-planar molecules with one or two hydrogen bond acceptors ([@B74], [@B75]). The CYP2B6 substrate selectivity comprises many diverse chemicals, including not only clinically used drugs but also many environmental chemicals such as pesticides ([@B132]; [@B49]; [@B135]). Therapeutically important drugs metabolized primarily by CYP2B6 include the prodrug cyclophosphamide, which is converted to the direct precursor of the cytotoxic metabolites, phosphoramide mustard and acrolein, by 4-hydroxylation ([@B55]; [@B115]), the non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz, which is 8-hydroxylated to become pharmacologically inactive ([@B140]; [@B21]), the atypical antidepressant and smoking cessation agent bupropion, which is converted to pharmacologically active hydroxybupropion ([@B30]; [@B48]; [@B134]), the anesthetics propofol ([@B15]; [@B97]) and ketamine ([@B20]), the analgesic pethidine (meperidine; [@B107]); the μ-opioid receptor agonist, methadone ([@B131]), the antimalarial artemisinin ([@B125]; [@B5]), among numerous additional metabolic pathways of other drugs, to which CYP2B6 contributes in part, such as the antiretroviral, nevirapine ([@B29]), and many others ([@B135]). Metabolic pathways suitable as probe for CYP2B6 activity include S-mephenytoin *N*-demethylation ([@B65]), bupropion hydroxylation ([@B30]; [@B35]) and efavirenz, based on *in vitro* investigations ([@B140]; [@B21]).

Endogenous substances metabolized by the enzyme include arachidonic acid, lauric acid, 17beta-estradiol, estrone, ethinylestradiol, and testosterone 16α- and 16β-hydroxylation ([@B25]).

Cytochrome P450 2B6 furthermore participates in the biotransformation of the abused drug "ecstasy" (*N-*methyl-3,4-methylenedioxymethamphetamine, MDMA), which is *N-*demethylated leading to potentially neurotoxic metabolites ([@B67]). It also plays a minor role in nicotine metabolism ([@B148]; [@B147]). CYP2B6 has furthermore been found to be of importance in the metabolism of pesticides and other environmental chemicals and pollutants ([@B49]). In particular the bioactivating oxidation of the organophosphorus insecticides chlorpyrifos ([@B16]) and methyl parathion ([@B27]) to their more toxic oxon metabolites is mainly catalyzed by CYP2B6, a public health concern due to their worldwide use and documented human exposures ([@B28]). Further environmental substrates are the insecticide and endocrine disruptor methoxychlor, the extensively used insect repellent *N*,*N*-diethyl-*m*-toluamide ([@B19]), profenofos and other pesticides ([@B1]), as well as the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK; [@B121]), aflatoxin B1 ([@B14]), and others ([@B49]; [@B1]).

Several structurally unrelated drugs have been shown to inhibit CYP2B6 and many of them do that in a mechanism-based, irreversible manner ([@B132]; [@B135]). The thienopyridine derivatives clopidogrel and ticlopidine are prodrugs that selectively inhibit platelet aggregation and have been in clinical use for the prevention of atherothrombotic events for several years. Both of them are potent mechanism-based inhibitors of CYP2B6 ([@B112]; [@B155]). The established anticancer agent, thioTEPA (*N*,*N*′,*N*′′-triethylenethiophosphoramide) was also found to be a highly selective and mechanism-based CYP2B6 inhibitor ([@B105]; [@B44]; [@B113]). A comparison of several selective inhibitors revealed that 2-phenyl-2-(1-piperidinyl)propane is probably the most selective CYP2B6 inhibitor *in vitro* ([@B136]). Recent *in vitro*observations identified the progesterone receptor antagonist, mifepristone (RU486; [@B78]); the anti-Parkinsonian agent selegiline (the R-enantiomer of deprenyl; [@B122]), methadone ([@B2]), and tamoxifen ([@B122]) as potent mechanism-based inhibitors. *In vivo*drug--drug interactions have been reported, for example, between thioTEPA and cyclophosphamide ([@B56]), clopidogrel and bupropion ([@B133]), voriconazole and efavirenz ([@B79]; [@B58]), clopidogrel and efavirenz ([@B59]), and between ticlopidine and ketamine ([@B100]). Furthermore, certain non-pharmaceutical compounds like particular benzylpyridine derivatives have been characterized as very potent inhibitors of CYP2B6 ([@B66]) and have been utilized for structural modeling experiments ([@B38]).

PHARMACOGENETICS OF *CYP2B6*
============================

The *CYPalleles* website^[1](#fn01){ref-type="fn"}^ currently lists 37 distinct star-alleles, i.e., gene haplotypes with a distinct variant amino acid sequence or with demonstrated functional effect (last accessed: February 21st, 2013). More than 30 amino acid-changing single-nucleotide polymorphisms (SNPs) occur in different combinations and together with additional non-coding variants and many more SNPs not yet assigned to particular haplotypes. The worldwide variations in SNP frequencies have been reviewed recently ([@B77]). **Table [1](#T1){ref-type="table"}** lists the most important variants in terms of frequency and functional impact and summarizes updated structural, functional, and frequency information for different ethnicities. In addition to the *CYPallele* website, further valuable information about *CYP2B6* SNPs and pharmacogenetics are available on the websites of *The Pharmacogenomics Knowledgebase*^[2](#fn02){ref-type="fn"}^, the *NCBI portal for short genetic variations*, dbSNP^[3](#fn03){ref-type="fn"}^, the *1000 Genomes Catalog of Human Genetic Variation*^[4](#fn04){ref-type="fn"}^, as well as the NHLBI exome sequencing project^[5](#fn05){ref-type="fn"}^.

###### 

Summary data on selected genetic polymorphisms of *CYP2B6*.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CYP allele designation^[a](#T1fn01){ref-type="fn"}^   Key mutation(s)^[b](#T1fn02){ref-type="fn"}^ rs number           Location, protein effect   Allele frequencies^[c](#T1fn03){ref-type="fn"}^   Functional effect
  ----------------------------------------------------- ---------------------------------------------------------------- -------------------------- ------------------------------------------------- -----------------------------------------------------------------------------------------
  *CYP2B6\*4*                                           g.18053(c.516) A\>G rs2279343                                    K262R (isolated)           0.00 AA, Af\                                      ↑ Expression, moderate substrate-dependent effects
                                                                                                                                                    0.04 Ca\                                          
                                                                                                                                                    0.05--0.12 As                                     

  *CYP2B6\*5*                                           g.25505(c.1459) C\>T rs3211371                                   R487C                      0.01--0.04AA, Af\                                 ↓ Expression, in part compensated by ↑ specific activity
                                                                                                                                                    0.09--0.12 Ca\                                    
                                                                                                                                                    0.05--0.12 Hs\                                    
                                                                                                                                                    0.01--0.04 As                                     

  *CYP2B6\*6*                                           g.15631(c.516) G\>T rs3745274 and g.18053(c.785)A\>G rs2279343   Q172H\                     0.33--0.5 AA, Af\                                 ↓ Expression; ↓activity with efavirenz *in vivo*; some other substrates show ↑ activity
                                                                                                                         K262R                      0.10--0.21 As\                                    
                                                                                                                                                    0.14--0.27 Ca\                                    
                                                                                                                                                    0.62 PNG                                          

  *CYP2B6\*18*                                          g.21011(c.983)T\>C rs28399499                                    I328T                      0.04--0.08 AA\                                    ↓ Expression and activity
                                                                                                                                                    0.05--0.12, Af\                                   
                                                                                                                                                    0.01 HS\                                          
                                                                                                                                                    0.00 As, Ca, PNG                                  

  *CYP2B6\*22*                                          g.-82T\>C\                                                       promoter (TATA-box)        0.00--0.025 AA, Af, As\                           ↑ Expression and activity\
                                                        rs34223104                                                                                  0.024 Ca, Hs                                      ↑ Inducibility *in vitro*
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*According to *CYPallele* nomenclature homepage [http://www.cypalleles.ki](http://www.cypalleles.ki.se)*.

*Genomic (g.) and cDNA (c.) positions are given in bp*.

*Selected frequencies of individual ethnicities (AA, African American; Af African; As Asian; Ca Caucasian; Hs, Hispanic; PNG, Papua New Guineans) compiled from dbSNP <http://www.ncbi.nlm.nih.gov/>SNP and from the literature cited in the text*.

*CYP2B6\*6* AND EFAVIRENZ: *IN VIVO*, *EX VIVO*, *IN VITRO*
===========================================================

The most common variant allele in all populations studied to date harbors two amino acid changes, Q172H and K262R, and is termed *CYP2B6\*6.*This haplotype occurs in about 15 to over 60% of individuals, depending on ethnicity (**Table [1](#T1){ref-type="table"}**). Although additional variants occur in the promoter and in introns, their functional impact appears to be of limited relevance and will not be further discussed here ([@B68]; [@B47]; [@B51]).

Since the discovery that CYP2B6 is the major enzyme for efavirenz 8-hydroxylation ([@B140]), pharmacogenetic studies have linked the Q172H variant to elevated plasma concentrations of efavirenz, indicating decreased enzyme function *in vivo.* This finding has been reproduced manifold in different ethnicities throughout the world (summarized by [@B128]; [@B106]). Three CYP2B6 polymorphisms, 15631G\>T, 21011T\>C, and an intron 3 SNP rs4803419, were also shown to be associated with efavirenz pharmacokinetics at genome wide significance ([@B52]).

The potent first-generation NNRTI of HIV-1 is recommended as initial therapy with two NRTIs in highly active antiretroviral therapy (HAART) regimes, but patients with subtherapeutic plasma concentrations can develop resistance and treatment failure, whereas those with too high plasma levels are at increased risk of central nervous system (CNS) side effects, which can lead to treatment discontinuation in a fraction of patients ([@B63]). Q172H variant was furthermore associated with increased neurotoxicity and other CNS side effects ([@B42]; [@B63]; [@B81]; [@B111]; [@B83]) with HAART-induced liver injury ([@B151]), and with efavirenz treatment discontinuation and the associated risk of developing drug resistance ([@B110]; [@B80]; [@B143]). Importantly, compound heterozygotes of 516T and another low activity allele (e.g., *\*11*,*\*18*,*\*27*,*\*28*) also predict high efavirenz plasma levels ([@B114]; [@B111]). In prospective, genotype-based dose adjustment studies the therapeutic dose of efavirenz could be successfully reduced and CNS-related side effects decreased ([@B36]; [@B37]). Using pharmacokinetic modeling and simulation it was suggested that *a priori*dose reduction in homozygous *CYP2B6\*6* patients would maintain drug exposure within the therapeutic range in this group of patients ([@B96]).

The *in vitro*data that have accumulated over the years on the *CYP2B6\*6*allele draw a more complex picture with functional consequences on various levels including pre-mRNA splicing, protein expression, as well as substrate-dependent changes in enzyme activity and different sensitivity toward irreversible inhibition. While early studies using recombinantly expressed enzyme variants found higher 7-ethoxycoumarin O-deethylase activity for the Q172H variant ([@B3]; [@B60]), in genotyped human livers (*ex vivo*), the *\*6*allele has been associated with approximately 50--75% decreased protein levels ([@B69]; [@B21]; [@B51]). An explanation for decreased protein expression was provided based on the observation that the c.516G\>T SNP coding for Q172H in exon 4 (rs3745274, **Table [1](#T1){ref-type="table"}**) was correlated to increased amounts of a hepatic splice variant that lacked exons 4--6, and concurrently to decreased amounts of the normal functional transcript. Recombinant expression of minigene constructs in mammalian cells proved that the c.516G\>T variant was causally involved in erroneous splicing and lower expression of functional mRNA and protein ([@B51]). It has been hypothesized that binding of splice factors to an exonic splicing enhancer(s) located in exon 4 could be affected by the variant ([@B153]; [@B116]). Although reduced expression in liver appears to satisfactorily explain increased efavirenz plasma concentrations in individuals with *\*6/\*6*genotype ([@B21]), recent *in vitro*data of expressed variants seem to indicate that the amino acid substitutions contribute to changes in catalytic activity of the enzyme. Structurally this is not easy to comprehend, because the Q172H and Lys262Arg amino acid changes occur in regions of the protein that are not directly located at the active site or that have been identified as substrate recognition sites (**Figure [2](#F2){ref-type="fig"})**.

![**CYP2B6 structural model**. Selected variant residues are marked in green (Q172H, K262R, I328T, R487C); substrate recognition sites (SRS; [@B94]) and active site residues (ASR; [@B95]) are highlighted in blue; the prosthetic heme molecule is shown in red. PDB file 3IBD was visualized using VMD visual molecular dynamics viewer <http://www.ks.uiuc.edu/Research/vmd/> ([@B57]). The protein sequence used for determining the crystal structure contains R at position 262 instead of the reference residue K. **(A)** view along *x*-axis (light red); **(B)** view along *y*-axis (light green); **(C)** view along *z*-axis (light blue)](fgene-04-00024-g002){#F2}

Concerning efavirenz and also other substrates, the available *in vitro* data are however, not well in agreement with each other. **Table [2](#T2){ref-type="table"}** summarizes kinetic parameters for bupropion and efavirenz for CYP2B6 enzyme variants obtained from different recombinant expression systems. Using *Escherichia coli*expression system, [@B156] purified six *N-*terminally truncated expressed variants to homogeneity and reconstituted them with NADPH:cytochrome 450 reductase (POR) at a molar ratio of 1:2 and measured efavirenz and bupropion kinetics. Using Sf9 insect cell cotransfection, CYP2B6.1, 2B6.4 and 2B6.6 were expressed in the presence of 10-fold excess of POR, i.e., under saturating conditions, to measure efavirenz kinetics ([@B4]). Another study determined both bupropion and efavirenz kinetics in protein preparations also derived from insect cells in the presence or absence of cytochrome b5 (CYB5) but at somewhat more variable ratios in regard to POR ([@B146]). [@B104] used the COS-1 expression system, where P450 monooxygenase activity is supported by endogenously expressed POR, to determine bupropion and efavirenz kinetics for several novel CYP2B6 variants in comparison to the known variants 2B6.1, 2B6.5, and 2B6.6.

###### 

Kinetic properties of recombinantly expressed CYP2B6 protein variants with bupropion and efavirenz.

  Variant   System      Bupropion hydroxylation   Efavirenz 8-hydroxylation   Reference                       
  --------- ----------- ------------------------- --------------------------- ----------- ------ ------ ----- ---------
  2B6.1     COS-1       87                        100                         100         2.07   100    100   [@B104]
            *E. coli*   95                        100                         100         7.3    100    100   [@B156]
            Sf9                                                                           7.7    100    100   [@B4]
            Sf9         64                        100                         100         3.2    100    100   [@B146]
  2B6.6     COS-1       72                        81                          98          1.21   107    183   [@B104]
            *E. coli*   380                       175                         43          198    563    20    [@B156]
            Sf9                                                                           12.4   81     50    [@B4]
            Sf9         63                        139                         143         8.8    133    49    [@B146]
  2B6.4     *E. coli*   162                       60                          35          5.5    73     96    [@B156]
            Sf9                                                                           9.16   169    142   [@B4]
  2B6.5     COS-1       65                        44                          59          1.15   46     83    [@B104]
            *E. coli*   134                       66                          47          53     1005   138   [@B156]
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The compilation of data in **Table [2](#T2){ref-type="table"}** shows that differences between the variants were masked by differences between the expression systems. For example, efavirenz *K*~m~ was moderately decreased (58%) for COS-1 cell-expressed 2B6.6 compared to 2B6.1 but moderately larger for both insect cell-expressed proteins. The *E. coli*-expressed variant showed, however, 27-fold increased *K*~m~. While the COS-1 proteins had almost identical *V*~max~, one of the insect cellproteins had decreased *V*~max~ (81%), while the other had increased activity (133%). Again, the *E. coli*-expressed variant showed the biggest difference of almost sixfold higher activity for the variant. Similar discrepancies, albeit less dramatic, were found with bupropion as substrate (**Table [2](#T2){ref-type="table"}**).

This data-comparison illustrates the problems that still exist with recombinant P450 expression systems, and particularly for CYP2B6, which appears to be an enzyme that sensibly reacts with activity changes to expression conditions. It is difficult to pin down the reasons for these differences exactly. Reconstitution of recombinant or even purified P450 with POR and CYB5 is a non-trivial problem especially if different protein variants shall be compared for quantitative kinetic parameters. Reconstitution under saturating conditions with respect to electron donators, e.g., at a POR:P450 ratio of 10, is a straightforward practical way, but in hepatocytes, POR is stoichiometrically underrepresented (ratio about 1:10) and may be limiting for monooxygenase activity ([@B40]). Enzyme variants may interact differently with the electron donors and catalytic differences could thus depend on reconstitution conditions. In addition, *N-*terminal modifications required to achieve high expression in *E. coli*may interact with the DNA-polymorphisms to be analyzed. In the COS-cell system, on the other hand, the POR:P450 ratio can neither be controlled nor quantified because expression of P450 is too low for spectral quantitation.

Taken together, the data from expression systems indicated that catalytic differences may exist between CYP2B6.6 and CYP2B6.1. However, except for the *E. coli*study, the differences were rather modest and at present it cannot be concluded with certainty whether the CYP2B6.6 variant is catalytically more or less active compared to the wild-type, atleast for bupropion and efavirenz. Taken all evidence together, the decrease in hepatic expression due to erroneous splicing caused by the c.516G\>T SNP ([@B21]; [@B51]) most plausibly explains most of the phenotypic *in vivo*activity differences observed with efavirenz and bupropion.

*CYP2B6\*6*SNP-related functional differences were also observed with inhibitors. In contrast to the wild-type enzyme the recombinantly expressed K262R variant was not inactivated by efavirenz, but both enzymes were irreversibly inhibited by 8-hydroxyefavirenz ([@B8]; [@B7]). Lower susceptibility to inhibition of the K262R variant and the CYP2B6.6 double variant compared to CYP2B6.1 was also found with respect to sertraline and clopidogrel, as well as several other potent drug inhibitors of CYP2B6 ([@B127]). These data indicate a role of genetic polymorphisms in drug--drug interaction sensitivity of CYP2B6, a finding that warrants further investigation *in vivo*.

OTHER *CYP2B6* VARIANTS AND OTHER SUBSTRATES -- *IN VITRO* STUDIES
==================================================================

The two amino acid changes that together constitute the *\*6*allele also occur in isolation, although at much lower frequencies ([@B64]; [@B154]; **Table [1](#T1){ref-type="table"}**). In most pharmacogenetic studies they are not being determined and functional data is therefore rare, especially concerning *\*9* ([@B64])*.*Data from recombinant systems as well as liver data suggest that the K262R variant possesses catalytic activities similar to the wild-type enzyme, although with different substrates moderately increased or decreased activity was observed (**Tables [2](#T2){ref-type="table"}** and **[3](#T3){ref-type="table"}**; [@B21]; [@B51]). The allele with amino acid change \[R487C\] in exon 9 (*\*5*variant; **Table [1](#T1){ref-type="table"}**) expresses very low levels of protein which does not translate into similarly reduced activities as measured with bupropion as well as efavirenz ([@B69]; [@B21]; [@B51]). The variant was shown to have higher specific activity compared to wild-type ([@B104]). In human liver, this leads to partial compensation of low expression, finally resulting in a phenotype with moderately decreased activity with bupropion and efavirenz *in vivo*. This explains why *CYP2B6\*5*was not associated with efavirenz pharmacokinetics in HIV patients ([@B10]).

###### 

Properties of recombinantly expressed CYP2B6 protein variants with other clinical substrates.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
          Artemether^[1](#T2fn01){ref-type="fn"}^\   Selegiline^[2](#T2fn02){ref-type="fn"}^\   Chlorpyrifos^[3](#T2fn03){ref-type="fn"}^\   Cyclophosphamide^[4](#T2fn04){ref-type="fn"}^\   Cyclophosphamide^[4](#T2fn04){ref-type="fn"}^\                             
          COS-7 cells ([@B53])                       COS-7 cells ([@B141])                      COS-1 cells ([@B16])                         Sf9 cells ([@B4])                                *E. coli* ([@B103])                                                        
  ------- ------------------------------------------ ------------------------------------------ -------------------------------------------- ------------------------------------------------ ------------------------------------------------ ------ ------ ----- ----- -------
  2B6.1   3.1                                        100                                        48.2                                         100                                              1.84                                             100    2.68   100   3.6   100

  2B6.6   6.72                                       416                                        56.6                                         169                                              1.97                                             254    1.62   99    4.0   155.2

  2B6.4   2.73                                       196                                        45.8                                         147                                              1.09                                             1094   2.75   74    3.5   67.1

  2B6.5   6.87                                       55                                         70.1                                         85                                               0.80                                             441                 5.1   72.4
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*O-Demethylation*.

*N-Demethylation (mean values were calculated for several expressions of CYP2B6.1)*.

*Desulfation*.

*4-Hydroxylation*.

The second most important functionally deficient allele is *CYP2B6\*18*(c.983C\>T \[I328T\]), which occurs predominantly in African subjects with allele frequencies of 4--11% ([@B85]; [@B77]). The I328T variant expressed no detectable protein or activity toward bupropion, 7-ethoxy-4-trifluoromethylcoumarin (7-EFC), selegiline and artemether in COS-1 cells whereas a partially defective protein was expressed in insect cells ([@B64]; [@B141]; [@B53]). This demonstrates another example for expression system-dependent differences. Most likely the 2B6.18 variant is temperature-sensitive and thus able to be expressed at the lower temperature (27°C) of insect cell culture but not at 37°C. Interestingly, the I328T+Q172H double variant expressed partially functional protein in HEK293 cells and in yeast ([@B138]), indicating that Q172H can stabilize the I328T variant. The *\*18*allele is thus phenotypically a null allele, at least *in vitro*with some substrates. This is supported by many *in vivo* studies (see below).

At least 12 additional null or low-activity alleles have been described and analyzed with various substrates ([@B70]; [@B64]; [@B114]; [@B141]; [@B53]). Although they are rather rare in all investigated populations they may have profound effects on drug metabolism if present in compound heterozygous genotypes, e.g., in combination with *\*6*or *\*18*([@B114]). The *CYP2B6\*22*allele is a gain-of-function variant associated with increased transcription *in vitro*([@B157]) and with increased activity *in vivo*([@B114]). It was shown that a -82T\>C exchange alters the TATA-box into a functional CCAAT/enhancer-binding protein binding site that causes increased transcription from an alternative downstream initiation site ([@B157]). Interestingly, the -82T\>C polymorphism also confers synergistically enhanced *CYP2B6* inducibility by the PXR ligand rifampicin in human primary hepatocytes ([@B76]).

New variants are discovered preferentially in previously uncharacterized ethnic groups. [@B109] described two novel combinations of known amino acid variants in a Colombian population. Structural variants including a novel CYP2B6/2B7P1 duplicated fusion allele (*CYP2B6\*30*) were found when individuals from various ethnicities were screened for copy number variations ([@B84]). Furthermore, three novel and five previously uncharacterized amino acid variants in different combinations (*CYP2B6\*33* t*o \*37*) were identified by resequencing the *CYP2B6*gene in a Rwandese cohort of HIV-1-infected patients ([@B104]). The variants were then functionally studied by COS-1 cell expression and by *in silico* prediction tools. At least four of the variants were shown to result in complete or almost complete loss of function with bupropion and efavirenz as substrates. The detailed comparison of *in vitro* functionality of the variants with *in silico* prediction tools including a thorough substrate docking simulation analysis points at the challenge to deal with the hundreds of new variants that exist in all populations as currently uncovered by next generation sequencing approaches and large scale population projects (see links above).

CLINICAL STUDIES WITH DIFFERENT DRUGS
=====================================

The widely used anticancer and immunosuppressant prodrug cyclophosphamide depends on bioactivation to 4-hydroxycyclophosphamide for cytotoxic activity. Bioactivation is highly variable in cancer patients and has been attributed mainly to CYP2B6 *in vitro*and *in vivo*with contributions from CYP2C19 and CYP3A4 ([@B12]; [@B103]). The case of cyclophosphamide 4-hydroxylation deserves particular attention, as it exemplifies substrate-dependent effects of CYP2B6 pharmacogenetics. Cyclophosphamide 4-hydroxylation was initially reported to be enhanced in livers genotyped *CYP2B6\*6/\*6*([@B145]), which was confirmed in several later *in vivo*studies ([@B144]; [@B91]; [@B130]). However, other *in vivo* studies analyzing pharmacokinetics or clinical outcome also presented contradictory or negative results ([@B120]; [@B24]; [@B86]; [@B150]; [@B103]). *In vitro,*insect cell-expressed recombinant CYP2B6.4 \[K262R\] had lower activity for cyclophosphamide 4-hydroxylation ([@B4]; [@B103]). The CYP2B6.4 and CYP2B6.6 variants thus display mirror-inverted catalytic activities toward efavirenz and cyclophosphamide, in that the former variant is the catalytically more active one with efavirenz, whereas the opposite is true for the latter variant (**Table [3](#T3){ref-type="table"}**). A direct comparison of catalytic properties of the two variants with the reference enzyme expressed in insect cells supports this inverse behavior of the two variants toward these two substrates ([@B4]). Interestingly, several studies associated other variants including *CYP2B6\*4, \*5, \*8*,and *\*9*with lower 4-OH cyclophosphamide formation *in vivo*or with worse outcome ([@B126]; [@B6]; [@B46]; [@B61]). Taken together, the data concerning cyclophosphamide from both *in vivo* and *in vitro*indicate that *CYP2B6* polymorphism plays a role, although the studies are so far not yet conclusive. This may be explained by different study size design as well as lack of consistency in allele definition and genotype information among studies ([@B45]).

In addition to efavirenz, *CYP2B6* genotype also affects plasma levels of the antiretroviral drug nevirapine ([@B101]; [@B82]). The impact of the *CYP2B6* 516G\>T polymorphism on nevirapine exposure was confirmed and quantified in a pharmacometric analysis of nevirapine plasma concentrations from 271 patients genotyped for 198 SNPs in 45 ADME (absorption, distribution, metabolism, and excretion) genes and covariates ([@B72]). Moreover, nevirapine-related cutaneous adverse events, which are most likely major histocompatibility complex (MHC) class I-mediated, were significantly influenced by *CYP2B6*polymorphism while hepatic side effects, most likely MHC class II-mediated, were unaffected by *CYP2B6* ([@B152]).

*CYP2B6*allele variants were also investigated in the context of the synthetic μ-opioid receptor agonist, methadone, which is metabolized by CYPs 3A4/5, 2B6, and 2D6, and used as a maintenance treatment for opioid addiction. In *\*6/\*6*carriers (*S*)-methadone plasma levels were increased leading to potentially higher risk of severe cardiac arrhythmias and methadone associated deaths ([@B17]; [@B23]; [@B9]). Methadone dose requirement for effective treatment of opioid addiction was shown to be significantly reduced in carriers of this genotype ([@B73]).

CONCLUSION
==========

The polymorphism of the *CYP2B6* gene has initially been studied by reverse genetics approach, i.e., starting from the identification of genetic variants in DNA and liver samples, followed by *in vitro* characterization of genotyped livers and expressed variant proteins. Clinical studies have then contributed to identify the variants that are important *in vivo*, and *in vitro* studies are again needed to identify and mechanistically explain causal variants. Nevertheless, C*YP2B6* pharmacogenetics has yet to be fully explored, especially with respect to combined effects of the involved variants on both expression and catalytic properties, the latter of which additionally depend on the substrate. While the relevance for HIV-1 therapy with efavirenz is well established and translational approaches have already been clinically tested, an increasing number of studies suggest clinical relevance for additional drug substrates.
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